Effects of dietary flavonoids, luteolin, and quercetin on the reversal of epithelial-mesenchymal transition in A431 epidermal cancer cells. 2011

Yung-Sheng Lin, and Pei-Hsun Tsai, and Chithan C Kandaswami, and Chia-Hsiung Cheng, and Ferng-Chun Ke, and Ping-Ping Lee, and Jiuan-Jiuan Hwang, and Ming-Ting Lee
Institute of Biochemical Sciences, College of Life Sciences, National Taiwan University, Taipei, Taiwan.

Highly invasive A431-III cells, which are derived from parental A431-P cells, were originally isolated by three successive passages through a Boyden chamber using a Matrigel-coated membrane support. The greater invasion potential shown by A431-III cells was due to their increased ability to spread/migrate, which was associated with enhanced MMP activity. The tumor progression events evoked by A431-P cells compared to A431-III cells may help identify useful strategies for evaluating the epithelial-mesenchymal transition (EMT) and these cell lines could be a reliable model for evaluating tumor metastasis events. Using this approach, we evaluated the effects of luteolin and quercetin using the A431-P/A431-III EMT model. These flavonoids reversed cadherin switching, downregulated EMT markers, and nullified the invasion ability of A431-III cells. Overexpression of MMP-9 resulted in induction of the EMT in A431-P cells and this could be reversed by treating with luteolin or quercetin. Cotreatment of A431-P and A431-III cells with epidermal growth factor (EGF) plus luteolin or quercetin resulted in a more epithelial-like morphology, led to reduced levels of EGF-induced markers of EMT, and caused the restoration of cell-cell junctions. E-cadherin was decreased by EGF, but increased by luteolin and quercetin. Our results suggest that luteolin and quercetin are potentially beneficial agents that target and prevent the occurrence of EMT in epidermal carcinoma cells. These chemicals also have the ability to attenuate tumor progression in A431-III cells. Luteolin and quercetin show inherent potential as chemopreventive/antineoplastic agents and do this by abating tumor progression through a reversal of EMT.

UI MeSH Term Description Entries
D007365 Intercellular Junctions Direct contact of a cell with a neighboring cell. Most such junctions are too small to be resolved by light microscopy, but they can be visualized by conventional or freeze-fracture electron microscopy, both of which show that the interacting CELL MEMBRANE and often the underlying CYTOPLASM and the intervening EXTRACELLULAR SPACE are highly specialized in these regions. (From Alberts et al., Molecular Biology of the Cell, 2d ed, p792) Cell Junctions,Cell Junction,Intercellular Junction,Junction, Cell,Junction, Intercellular,Junctions, Cell,Junctions, Intercellular
D009361 Neoplasm Invasiveness Ability of neoplasms to infiltrate and actively destroy surrounding tissue. Invasiveness, Neoplasm,Neoplasm Invasion,Invasion, Neoplasm
D010766 Phosphorylation The introduction of a phosphoryl group into a compound through the formation of an ester bond between the compound and a phosphorus moiety. Phosphorylations
D011794 Quercetin A flavonol widely distributed in plants. It is an antioxidant, like many other phenolic heterocyclic compounds. Glycosylated forms include RUTIN and quercetrin. 3,3',4',5,7-Pentahydroxyflavone,Dikvertin
D002465 Cell Movement The movement of cells from one location to another. Distinguish from CYTOKINESIS which is the process of dividing the CYTOPLASM of a cell. Cell Migration,Locomotion, Cell,Migration, Cell,Motility, Cell,Movement, Cell,Cell Locomotion,Cell Motility,Cell Movements,Movements, Cell
D004815 Epidermal Growth Factor A 6-kDa polypeptide growth factor initially discovered in mouse submaxillary glands. Human epidermal growth factor was originally isolated from urine based on its ability to inhibit gastric secretion and called urogastrone. Epidermal growth factor exerts a wide variety of biological effects including the promotion of proliferation and differentiation of mesenchymal and EPITHELIAL CELLS. It is synthesized as a transmembrane protein which can be cleaved to release a soluble active form. EGF,Epidermal Growth Factor-Urogastrone,Urogastrone,Human Urinary Gastric Inhibitor,beta-Urogastrone,Growth Factor, Epidermal,Growth Factor-Urogastrone, Epidermal,beta Urogastrone
D005419 Flavonoids A group of phenyl benzopyrans named for having structures like FLAVONES. 2-Phenyl-Benzopyran,2-Phenyl-Chromene,Bioflavonoid,Bioflavonoids,Flavonoid,2-Phenyl-Benzopyrans,2-Phenyl-Chromenes,2 Phenyl Benzopyran,2 Phenyl Benzopyrans,2 Phenyl Chromene,2 Phenyl Chromenes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000975 Antioxidants Naturally occurring or synthetic substances that inhibit or retard oxidation reactions. They counteract the damaging effects of oxidation in animal tissues. Anti-Oxidant,Antioxidant,Antioxidant Activity,Endogenous Antioxidant,Endogenous Antioxidants,Anti-Oxidant Effect,Anti-Oxidant Effects,Anti-Oxidants,Antioxidant Effect,Antioxidant Effects,Activity, Antioxidant,Anti Oxidant,Anti Oxidant Effect,Anti Oxidant Effects,Anti Oxidants,Antioxidant, Endogenous,Antioxidants, Endogenous
D012878 Skin Neoplasms Tumors or cancer of the SKIN. Cancer of Skin,Skin Cancer,Cancer of the Skin,Neoplasms, Skin,Cancer, Skin,Cancers, Skin,Neoplasm, Skin,Skin Cancers,Skin Neoplasm

Related Publications

Yung-Sheng Lin, and Pei-Hsun Tsai, and Chithan C Kandaswami, and Chia-Hsiung Cheng, and Ferng-Chun Ke, and Ping-Ping Lee, and Jiuan-Jiuan Hwang, and Ming-Ting Lee
July 2016, Journal of cardiovascular pharmacology,
Yung-Sheng Lin, and Pei-Hsun Tsai, and Chithan C Kandaswami, and Chia-Hsiung Cheng, and Ferng-Chun Ke, and Ping-Ping Lee, and Jiuan-Jiuan Hwang, and Ming-Ting Lee
November 1999, British journal of pharmacology,
Yung-Sheng Lin, and Pei-Hsun Tsai, and Chithan C Kandaswami, and Chia-Hsiung Cheng, and Ferng-Chun Ke, and Ping-Ping Lee, and Jiuan-Jiuan Hwang, and Ming-Ting Lee
May 2021, Medical oncology (Northwood, London, England),
Yung-Sheng Lin, and Pei-Hsun Tsai, and Chithan C Kandaswami, and Chia-Hsiung Cheng, and Ferng-Chun Ke, and Ping-Ping Lee, and Jiuan-Jiuan Hwang, and Ming-Ting Lee
February 2017, Journal of cellular physiology,
Yung-Sheng Lin, and Pei-Hsun Tsai, and Chithan C Kandaswami, and Chia-Hsiung Cheng, and Ferng-Chun Ke, and Ping-Ping Lee, and Jiuan-Jiuan Hwang, and Ming-Ting Lee
January 2020, Nutrition and cancer,
Yung-Sheng Lin, and Pei-Hsun Tsai, and Chithan C Kandaswami, and Chia-Hsiung Cheng, and Ferng-Chun Ke, and Ping-Ping Lee, and Jiuan-Jiuan Hwang, and Ming-Ting Lee
July 2012, Molecular medicine reports,
Yung-Sheng Lin, and Pei-Hsun Tsai, and Chithan C Kandaswami, and Chia-Hsiung Cheng, and Ferng-Chun Ke, and Ping-Ping Lee, and Jiuan-Jiuan Hwang, and Ming-Ting Lee
December 2020, Drug metabolism and pharmacokinetics,
Yung-Sheng Lin, and Pei-Hsun Tsai, and Chithan C Kandaswami, and Chia-Hsiung Cheng, and Ferng-Chun Ke, and Ping-Ping Lee, and Jiuan-Jiuan Hwang, and Ming-Ting Lee
September 2008, Acta pharmacologica Sinica,
Yung-Sheng Lin, and Pei-Hsun Tsai, and Chithan C Kandaswami, and Chia-Hsiung Cheng, and Ferng-Chun Ke, and Ping-Ping Lee, and Jiuan-Jiuan Hwang, and Ming-Ting Lee
October 2014, Molecular medicine reports,
Yung-Sheng Lin, and Pei-Hsun Tsai, and Chithan C Kandaswami, and Chia-Hsiung Cheng, and Ferng-Chun Ke, and Ping-Ping Lee, and Jiuan-Jiuan Hwang, and Ming-Ting Lee
January 2022, Advances in experimental medicine and biology,
Copied contents to your clipboard!